Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization(Roche / Genentech)은 Advanced Hepatocellular Carcinoma (HCC), 표적 항체로, Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy 영역에서 개발·상용화 중입니다. 전임상 단계입니다. ClinicalTrials.gov 기준 3건의 관련 임상이 등록되어 있습니다.
Advanced Hepatocellular Carcinoma (HCC),
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
Recruiting
biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or per
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Atezolizumab ± Bevacizumab and Yttrium-90 Radioembolization(Roche / Genentech)은 Advanced Hepatocellular Carcinoma (HCC), 표적 항체로, Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy 영역에서 개발·상용화 중입니다. 전임상 단계입니다. ClinicalTrials.gov 기준 3건의 관련 임상이 등록되어 있습니다.
Advanced Hepatocellular Carcinoma (HCC),
Advanced Hepatocellular Carcinoma (HCC), Classified as BCLC Stage B or C, Treated With a Combination of Selective Internal Radiation Therapy
Recruiting
biomarkers for regimen selection, de-escalation criteria, optimal sequencing, and integration with LRT or per
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.